GLP-1 is a hormone released by the small intestine after eating that slows digestion, raises insulin, and signals the brain that the body has had enough food. Rising public interest in weight-loss drugs that mimic this hormone has put the spotlight on how the natural system behind it actually functions, and what dietary factors are linked to it.
What GLP-1 Is and Where It Comes From
GLP-1, short for glucagon-like peptide-1, is a hormone produced mainly by L cells located in the lining of the small intestine, according to Cleveland Clinic. It is released into the bloodstream after a meal and belongs to a group of gut-derived signals, alongside hormones such as PYY and cholecystokinin, that tell the body a meal has been consumed, as described by My-Personaltrainer.
According to The Conversation, GLP-1 levels rise naturally for roughly two hours after eating. During that window, the hormone performs several jobs at once rather than acting on a single target.
How GLP-1 Signals Fullness to the Brain
Cleveland Clinic describes four linked actions of GLP-1: it triggers insulin release from the pancreas, blocks the release of glucagon so blood sugar does not rise unnecessarily, slows down stomach emptying, and increases the feeling of fullness after eating by acting on brain regions that process hunger signals.
My-Personaltrainer adds that the hormone's signal reaches the hypothalamus and brainstem, where it can also influence the brain's response to highly palatable food. The Conversation notes that appetite is closely tied to how strongly GLP-1 communicates with these brain regions, meaning hunger functions as a fluctuating signal shaped by digestion and gut hormones rather than a fixed personal trait.
Hunger is a fluctuating signal shaped by gut-derived hormones, digestion, activity and environment.
— The Conversation
Natural GLP-1 Versus GLP-1 Medications
Drugs such as semaglutide and liraglutide are classified as GLP-1 receptor agonists. Cleveland Clinic explains that an agonist is a manufactured substance that attaches to the same cell receptor as the natural hormone and produces a similar, but stronger and longer-lasting, effect. The Conversation states that these medications do not block hunger outright; instead, they extend the same post-meal satiety signal the body already produces, and effects on appetite recede once treatment stops because the drugs do not permanently reset the underlying regulatory system.
Natural GLP-1 Compared With GLP-1 Receptor Agonist Drugs
Feature
Natural GLP-1
GLP-1 receptor agonist drugs
Source
Released by L cells in the small intestine after eating (Cleveland Clinic)
Manufactured compound injected or taken orally (Cleveland Clinic)
Duration of effect
Rises for about two hours after a meal (The Conversation)
Designed to act over longer, sustained periods (Cleveland Clinic)
Same receptor pathway, amplified and prolonged (Cleveland Clinic)
Effect after stopping
Resumes normal meal-to-meal cycle
Appetite-reducing effect fades; weight regain commonly reported (The Conversation)
Why GLP-1 Is Getting Attention Now
Analyst firm Telsey, cited by Investing.com Italia, reported that GLP-1 drug adoption among all adults in the United States grew 364% between 2019 and 2024, with growth reaching 588% among people aged 18 to 39 and over 546% in Medicaid prescriptions over the same period. A July 2026 Axios survey cited in the same report found that 26% of respondents said they personally used a GLP-1 drug or knew someone who had in the prior three months, up from 4% in 2023.
The same analysis noted that an oral Wegovy pill launched in January 2026 and that a product called Foundayo received FDA clearance on April 1, 2026, and that retailers including Walmart and Costco reported an impact on pharmacy and consumer sales tied to the drugs' popularity, without the report detailing specific spending figures.
Dietary Factors Linked to GLP-1 Release
My-Personaltrainer reports that the overall composition of a meal, rather than any single food, is associated with how strongly GLP-1 is released. The source lists several dietary elements commonly associated with supporting this natural signal in research and nutrition guidance.
Soluble, fermentable fiber from legumes, oats, barley and vegetables rich in pectins and beta-glucans
Protein spread across meals from sources such as fish, legumes, eggs, lean dairy and white meat
Unsaturated fats, including olive oil, nuts and seeds
Complex carbohydrates from whole grains instead of refined flours and simple sugars
Eating at a slower pace and keeping regular meal timing
My-Personaltrainer also notes that sleep quality, stress levels and physical activity are described as additional factors that interact with this hormonal system, though the source does not quantify their individual effect on GLP-1 levels.
None of the sources reviewed claim that dietary changes alone reproduce the magnitude of appetite suppression achieved with GLP-1 receptor agonist medications; the comparison in available reporting is limited to the shared biological pathway, not equivalent effect size.
Questions
What exactly is GLP-1?
GLP-1 (glucagon-like peptide-1) is a hormone released by L cells in the small intestine after eating. It raises insulin, suppresses glucagon, slows stomach emptying and signals fullness to the brain, according to Cleveland Clinic.
Is GLP-1 the same as drugs like Ozempic or Wegovy?
No. GLP-1 is the body's own hormone. Medications such as semaglutide are GLP-1 receptor agonists, manufactured compounds that attach to the same receptor and produce a similar but stronger, longer-lasting effect, per Cleveland Clinic.
Can diet alone raise GLP-1 levels naturally?
My-Personaltrainer links higher GLP-1 activity to meals built around soluble fiber, spread-out protein, unsaturated fats and whole grains, but none of the sources reviewed suggest diet alone matches the appetite-suppressing effect of GLP-1 medications.
Does the appetite-reducing effect of GLP-1 last after stopping medication?
According to The Conversation, the effect fades once treatment stops because the drugs extend a natural signal temporarily rather than permanently resetting the body's appetite-regulating system.
Why is GLP-1 a trending topic now?
Analyst firm Telsey, cited by Investing.com Italia, reported sharp growth in GLP-1 drug use in the United States between 2019 and 2024, alongside new oral formulations entering the market or gaining regulatory clearance in 2026, which has increased public interest in how the underlying natural hormone works.
How the world is telling it
ItalianItalian outlets cover GLP-1 mainly through two angles: consumer-health guidance on foods and habits said to support the body's natural satiety hormone, and the commercial and market impact of GLP-1 weight-loss drugs, reflecting strong public interest in both the biology and the pharmaceutical boom around GLP-1.
This piece was prepared with artificial intelligence and passed an automated source check before publication. If you see an error, ask for a correction. Request a correction or reply · How we make this
People who reach 110 or beyond — known as supercentenarians — tend to share traits such as leanness, disease-free aging and steady daily routines, according to Spanish cardiologist Manuel de la Peña. He attributes 75% of longevity to lifestyle and only 25% to genes, but a 2026 genetics study puts heredity's share closer to 50–55%, showing researchers still disagree on how much is nature versus habit.
Hospital hand-washing sinks can turn into long-term reservoirs for antibiotic-resistant bacteria that colonize drain pipes and splash onto nearby counters, according to peer-reviewed research and hospital outbreak reports. Documented outbreaks in Toronto and Tokyo show that cleaning or replacing a sink alone did not stop transmission; cases ended only after facilities combined sink redesign, stricter cleaning schedules and changes to staff hand-hygiene routines.
A study published in the British Journal of Psychiatry on 20 October 2026 found that roughly a quarter of people with severe, recurrent or persistent depression show a pattern researchers call "circadian depression," tied to disrupted sleep-wake rhythms rather than mood alone. The University of Sydney-led team says this subtype responds less to standard antidepressants and more to treatments that target the body clock, such as light therapy and melatonin.
The FDA on October 19, 2026 classified a voluntary recall of more than 4.3 million tubes of toothpaste sold under the Brush Buddies, evo and ARU brands. The recall, covering children's products such as Barbie, Hot Wheels, My Little Pony and Crayola Silly Scents toothpaste, stems from manufacturing practice deviations; no illnesses have been reported.
